Skip to content

Treatment of Anaemia (Decrease in Red Blood Cells or Haemoglobin in Blood) with Unani medicine Habb-e-Khubs-ul-Hadeed

Clinical Validation of Unani Pharmacopoeial Formulation Habb-e-Khubs-ul-Hadeed in SÅ«â?? al-Qinya (Anaemia)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017822
Enrollment
240
Registered
2019-02-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Habb-e-Khubs-ul-Hadeed: 1 Tab orally twice daily with water after meals for 12 weeks Control Intervention1: nil: nil

Sponsors

Central Council for Research in Unani Medicine CCRUM
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: · Patients having mild (10.0-11.9 g/dL) to moderate (7.0-9.9 g/dL ) Anaemia · Patients of either sex in the age group 18-65 years. · Patients not taking any other drugs for SÅ«â?? al-Qinya (Anaemia)

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women 2. Patients having severe Anaemia (below 7gm/dl) 3. Patients having occult blood positive on stool examination. 4. Patients with chronic diseases requiring long-term treatment such as DM, T.B., HIV infection, leukemia, endocrine disorders, Haemorrhagic diathesis (hemophilia, ITP), bleeding piles, menorrhagia, metrorrhagia or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking study drug or could interfere with the interpretation of data. 5. Patients with concurrent serious hepatic, cardiac, renal or pulmonary dysfunction. 6. Patients not willing to report for follow up.

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptoms of SÅ«â?? al-Qinya (Anaemia)Timepoint: 12 weeks.

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: Investigations will be done at baseline and end of treatment

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026